Medicinal Products

Dáil Éireann Debate, Tuesday - 5 November 2024

• Díospóireachtaí
• Aimsigh díospóireacht
  • Díospóireachtaí na Dála
  • Díospóireachtaí an tSeanaid
  • Díospóireachtaí Coiste
• Aimsigh vótáil
  • Vótálacha na Dála
  • Vótálacha an tSeanaid
  • Vótálacha Coiste
• Ceisteanna Parlaiminte
  • Ceisteanna scríofa
  • Ceisteanna ó bhéal
• Leideanna cuardaigh
• Nuair a bhíonn tionchar tromchúiseach ag aithrisí

Tuesday, 5 November 2024

Ceisteanna (1131)

Brendan Griffin

Ceist:

1131. Deputy Brendan Griffin asked the Minister for Health further to Parliamentary Question No. 752 of 22 October 2024, when the HSE will meet the manufacturer to reconsider the possible approval of the reimbursement of palforzia for the treatment of peanut allergy; and if he will make a statement on the matter. [44435/24]

Freagraí scríofa

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• An Freagra Roimhe Sin
• An Chéad Fhreagra eile